SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

NCT04269642 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Parkinson's Disease

Interventions

DRUG: PT320 2.0mg Placebo
DRUG: PT320 2.0 mg
DRUG: PT320 2.5 mg

Sponsor

Peptron, Inc.